

AGENDA

JW Marriott Washington DC, 1331 Pennsylvania Avenue, NW

Wednesday, February 26

- 7:30am- 5:00pm Grant Review Committee Meeting (by invitation).....Salon I
- 12:00-5:30pm Melanoma Patients, Advocates & Foundations ForumSalon IV
- 4:00-8:00pm *Retreat Registration open*.....*Foyer of Penn Avenue Terrace*
- 6:00-7:30pm **Opening Reception**.....**Penn Avenue Terrace**

Thursday, February 27

- 6:30am-6:00pm *Registration*.....*Foyer of Salon III & IV*
- 7:00-8:15am General Breakfast.....Salon II
- 7:00-8:15 am Young Investigators Breakfast (by invitation).....Salon I
- 8:30-8:45am Opening Remarks Day 1**.....**Salon III & IV**
Michael Kaplan, MRA President & CEO
Marc Hurlbert, MRA Chief Science Officer
Grace Wenzel, Patient Advocate
- 8:45-9:15am Lecture**
Jedd Wolchok, Memorial Sloan Kettering Cancer Center: Maintaining innovation: New directions in melanoma research
- 9:15-11:25am Session 1: Novel therapeutic approaches for treating melanoma**
Chair: Ronit Satchi-Fainaro, Tel-Aviv University
- 9:15-9:40 **Thorsten Mempel, Massachusetts General Hospital:** CARMA1 in control of regulatory T cell function in melanoma
- 9:40-10:05 **Elaine Fuchs, The Rockefeller University:** How skin stem cell biology can guide us to the basis for tumor relapse
- 10:05-10:20 *Break*
- 10:20-10:40 **Nick Huntington, Monash University:** Effective melanoma immunity by targeting NK cell checkpoints
- 10:40-11:00 **Rizwan Haq, Dana-Farber Cancer Institute:** Melanoma selective cytotoxicity achieved through a novel switchable kinase inhibitor

11:00-11:25 **Richard White, Memorial Sloan Kettering Cancer Center:** Why tumors appear where they do: positional memory in the pathogenesis of acral melanoma

11:25-11:55am **Lecture: Padmanee Sharma, University of Texas MD Anderson Cancer Center:** From the clinic to the lab: Investigating response and resistance mechanisms to immune checkpoint therapy

11:55am-12:05pm *Transition to lunch*

12:05-1:05pm **Networking Lunch and General Roundtables #1.....Salon I & II**
Seating at roundtables limited by prior registration. Additional tables with open seating available for general networking and/or scheduled meetings. Topics are:

- | | |
|---|---|
| 1. Acral melanoma; | 11. Overcoming resistance to IO/targeted therapies; |
| 2. AI/imaging/diagnostics; | 12. Pediatric and young adult melanoma; |
| 3. Brain metastasis and leptomeningeal; | 13. Predictive, diagnostic & prognostic biomarkers; |
| 4. Cell therapy (ACT, TIL, etc); | 14. Prevention & early detection; |
| 5. Clinical trials: multi-site and patient recruitment; | 15. Role of genetics, genomics, & epigenomics; |
| 6. Founding your own company; | 16. Single-cell technologies sequencing and imaging; |
| 7. IO-understanding immune-related adverse events; | 17. Targets: finding/validating new targets & drug discovery; |
| 8. Microbiome; | 18. Treatment: combos, sequencing, and duration of treatment; |
| 9. MRA dermatology fellows; | 19. Tumor microenvironment; |
| 10. Neoadjuvant and adjuvant treatments; | 20. vaccines & intralesional therapies. |

12:00-2:00pm Scientific Advisory Panel meeting and lunch (by invitation).....The Senate Room

1:05-1:20pm *Transition to general session room (Salon III & IV)*

1:20-2:30pm **Session 2: Understanding melanoma metastasis**
Chair: Ashani Weeraratna, Johns Hopkins University

1:20-1:45 **Eva Hernando, New York University:** Melanoma-secreted Amyloid Beta Suppresses Neuroinflammation and Promotes Brain Metastasis

1:45-2:05 **Florian Karreth, Moffitt Cancer Center:** MicroRNA deregulation in melanoma progression

2:05-2:30 **Carmit Levy, Tel Aviv University:** Identification of novel regulators of melanoma brain metastasis

2:30-2:50pm *Break*

2:50-4:00pm **Session 3: Special Focus - Acral Melanoma**
Chair: Nick Hayward, QIMR Berghofer Medical Research Institute

2:50-3:15 **Boris Bastian, University of California, San Francisco:** The genetics of acral melanoma

- 3:15-3:35 **Phyu Aung, University of Texas MD Anderson Cancer Center:** Acral melanoma – histologic and molecular studies
- 3:35-4:00 **Ruth Halaban, Yale University and Aaron Newman, Stanford University:** Recurrent patterns of structural variation promote tumorigenesis in acral melanoma
- 4:00-4:30pm Lecture: James Allison, University of Texas MD Anderson Cancer Center:** Immune checkpoint blockade in cancer therapy: Historical perspective, new opportunities, and prospects for cures
- 4:30-4:35 **Closing Remarks Day 1**
Kristen Mueller, MRA Senior Director, Scientific Program
- 4:45-6:15pm Young Investigator, Dermatology Fellow, and Pilot Awardee Poster Session.....Penn Avenue Terrace**
All retreat attendees encouraged to attend
- 4:45-5:45pm ACS-MRA grant awardees reception (by invitation).....State Room
- 6:30-9:00 pm Reception and Dinner.....Zaytinya***
Dress: Casual 701 9th St NW
Reception: 6:30-7:00pm; Dinner 7:15pm

Friday, February 28

- 6:30-10:00am *Registration open.....Foyer of Salon III & IV*
- 7:00-8:30am Networking Breakfast and General Roundtables #2.....Salon I & II**
Seating at roundtables limited by prior registration. Additional tables with open seating available for general networking and/or scheduled meetings. Topics are:
- | | |
|---|--|
| 1. Clinical trials: Benefits and impediments to Phase 1 trials; | 9. Prevention & early detection – melanoma initiation; |
| 2. Founding your own company; | 10. Role of genetics, genomics & epigenomics in melanoma; |
| 3. Sex-related biology and melanoma; | 11. Surgery: current and emerging methods of surgical treatment; |
| 4. Heterogeneity and phenotype switching | 12. Targets: finding/validating new targets & drug discovery; |
| 5. IO – understanding immune-related adverse events; | 13. Tumor metabolism and metabolomics; |
| 6. Melanoma metastases – dormancy; | 14. Tumor microenvironment; |
| 7. Overcoming resistance to IO/targeted therapies; | 15. Understanding the biology of in-transit melanoma; |
| 8. Predictive, diagnostic & prognostic biomarkers; | 16. Uveal & mucosal melanoma; |
| | 17. Women in melanoma research & care. |
- 7:00-8:30 am Industry Roundtable Breakfast (by invitation).....Salon FG

8:40-8:45 m	Opening Remarks Day 2 Salon III & IV Kristen Mueller
8:45-9:15am	Lecture: Christian Blank, Netherlands Cancer Institute: Neoadjuvant approaches for treating melanoma
9:15-10:25am	Session 4: Understanding melanoma initiation to improve patient outcomes Chair: Sheri Holmen, Huntsman Cancer Institute at University of Utah
9:15-9:40	Chengyu Liang, University of Southern California: Molecular mechanisms of UV-induced mutagenesis in melanoma
9:40-10:00	Eleonora Leucci, Katholieke Universiteit Leuven: LncRNAs as modulators of protein synthesis rewiring in melanoma
10:00-10:25	Lorenz Studer, Memorial Sloan Kettering Cancer Center: Cell of origin as a driver of heterogeneity in melanoma
10:25-10:45	<i>Break</i>
10:45-11:30am	Session 5: Novel approaches for diagnosing melanoma and assessing therapeutic efficacy Chair: Christin Burd, Ohio State University
10:45-11:05	Ashish Kulkarni, University of Massachusetts, Amherst: Nanoscale Approaches for Targeting Tumor-associated Macrophages
11:05-11:30	Joann Elmore, University of California, Los Angeles: The importance of applying AI to assess histologic features to improve melanoma diagnosis
11:30am-12:15pm	Panel Discussion: Maintaining the momentum: New directions in melanoma research Moderator: Michael Atkins, Georgetown University, Chair of MRA Medical Advisory Panel <ul style="list-style-type: none"> • Susan Swetter, Stanford University • Suzanne Topalian, Johns Hopkins University, Chair of MRA Scientific Advisory Panel, MRA Board of Directors • Richard Carvajal, Columbia University • Marisol Soengas, Spanish National Cancer Research Center • Lorenzo Cohen, University of Texas MD Anderson Cancer Center
12:15pm-12:30pm	Closing Remarks Michael Kaplan and Marc Hurlbert
12:30-1:30 pm	Lunch and Departures Salon II
12:30-6:00 pm	Lunch and Melanoma Models Workshop (Chaired by Dr. Liz Patton and Dr. Glenn Merlino) (by invitation)..... Salon I